Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients.

Viral immunology - 1 Nov 2016

El Edel Rawhia H, Essa Enas Said, Essa Abdallah S, Hegazy Sara A, El Rowedy Dalia I

Abstract excerpt

Association between variable agent-induced hepatocellular carcinoma (HCC) and both PAI-1 4G/5G polymorphism and plasminogen activator inhibitor (PAI-1) levels compared to healthy controls have been reported in earlier studies. We aimed to assess serum PAI-1 and PAI-1 4G/5G polymorphism in hepatitis C virus (HCV)-induced HCC, HCV-induced liver cirrhosis, and viral infection-free apparently healthy control...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunosorbent Assay

Share to Hepacivirus

Share to Liver Cirrhosis

Share to Liver Neoplasms

Share to Plasminogen Activator Inhibitor 1

Share to Risk Factors

Source

Identifiers

PMID: 27459171
DOI: 10.1089/vim.2016.0027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients.PMID 27459171Read ↗

Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma.Semantic proximity Read ↗

PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.Semantic proximity Read ↗

Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Caucasian population.Semantic proximity Read ↗

Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.Semantic proximity Read ↗

Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance.Semantic proximity Read ↗

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.Semantic proximity Read ↗

Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.Semantic proximity Read ↗

Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.Semantic proximity Read ↗

Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.Semantic proximity Read ↗

Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.